On 1 October 2014, AmbulanzPartner and Ipsen Pharma are launching a research project to investigate the opportunities offered by digitalization and networking in complex outpatient spasticity treatment.
Through AmbulanzPartner.de, all those involved in spasticity treatment are networked in terms of information technology and services. The Internet portal connects specialists, pharmacists, providers of remedies and aids as well as patients and other roles authorized by the patient.
The use of AmbulanzPartner.de serves the purpose of care and quality management in spasticity treatment with botulinum toxin as well as the associated care and service research.
The worldwide unique scientific project is planned for a period of two years and will involve around 100 people with spasticity as a result of a stroke.
On December 4, 2025, the ALS app will be presented at the"ALS App Europe Initiative…
Following our last newsletter on the introduction of the OPM classification in the ALS app,…
You can now submit your e-prescription with your health card via the ALS app at…
We are pleased to introduce an important new feature in the ALS app today: The…
The THC:CBD patient survey is a systematic survey of 130 patients with amyotrophic lateral sclerosis…
We are pleased to inform you that we have completely revised our medication module. With…